

Press Release

Alligator Bioscience AB appoints Sibylle Lenz as Chief Executive Officer

Internationally experienced pharmaceutical executive will join Alligator Bioscience AB on 1st August 2010.

Lund, Sweden, June 14th 2010

Alligator Bioscience AB, a privately owned biotech company focusing on optimization of biopharmaceuticals using its proprietary protein optimization technology FIND®, announced today that it has appointed Sibylle Lenz, Pharm. Dr, as its new Chief Executive Officer (CEO). Mrs Lenz, who joins Alligator Bioscience from Dako A/S and who previously has had a long successful career at H. Lundbeck A/S, has significant senior management experience in the pharmaceutical industry and has been appointed to lead the Company as it embarks on a new phase of international clinical and commercial development. Mrs Lenz will take up her position on 1st August 2010.

Sibylle Lenz is an experienced pharmaceutical executive who has held senior positions in the diagnostics and pharmaceutical industry. She joins Alligator Bioscience from Dako A/S, a cancer diagnostics company where she was Vice President, Corporate Business Development.

From 2001 to 2008 Mrs Lenz held a number of senior international commercial positions in H. Lundbeck A/S and prior to that Mrs Lenz gained more than ten years of experience in different research and development positions, also in H. Lundbeck A/S. Mrs Lenz holds a PhD specialized in medicinal chemistry from the Danish University of Pharmaceutical Sciences.

"I am delighted to welcome Sibylle Lenz to Alligator Bioscience," said Mats Grahn, Alligator Biosciences Chairman. "She is an entrepreneurial business leader who has succeeded in building winning teams and delivered strong performance wherever she has worked. I am confident she will be equally successful in taking Alligator Bioscience forward as an innovative company in the field of creating and commercializing new drug candidates."

Sibylle Lenz commented: "I look forward to joining Alligator Bioscience at a time of great potential. The Company has achieved promising preclinical data with ADC-1004, a selective C5a receptor antagonist for the treatment of ischemic reperfusion injury and I believe this project can be brought successfully to market through partnerships on an international basis. Furthermore, accelerating IMCAN, the platform for cancer immunotherapy, will be a cornerstone in Alligator Biosciences future. I believe my commercial pharmaceutical experience will help us to establish and implement a winning international business strategy".